coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    West Central Manchester PCN, Manchester (LAD) · Health Inequalities Profile

    PCN U98408 · NHS Greater Manchester Integrated Care Board · 6 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    64,811

    Registered population

    71.2% aged 18–64

    10.8%

    Aged 65+

    ICB 14.9% · England 17.9%

    51.5%

    Ethnic minority (non-White)

    23.4% Asian · England 9.6%

    21.2%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~10,601

    Core20 residents (est.)

    Resident basis; registered basis ~13,799 · see page 3

    6,841

    Hypertension register

    +1.34% in 3 yrs · England +5.60%

    916

    SMI register

    9.7% of Manchester (LAD)'s

    831

    COPD register

    Reviews +13.03% in 3 yrs

    Forecast to 2030

    7,604

    Hypertension patients, 2030

    +763 on today

    68.5%

    QRISK ≥20% on statins, 2030

    +2.40pp over 3 yrs

    3.0%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    61.3 pp
    Core20 concentration spans 61.3 pp across practices.

    Practice Core20 shares range from 6.8% at Chorlton Family Practice to 68.0% at Princess Road Surgery, although the PCN matches England at 21.2% (21.0%).

    61.6%
    Hypertension control and SMI checks trail England.

    Hypertension treatment to target is 61.6% (England 70.3%) and SMI blood pressure checks reach 76.9% (England 83.4%), which may reflect recall gaps.

    79.5%
    Respiratory annual reviews exceed England despite register lags.

    COPD annual reviews reach 79.5% (England 76.4%, up +13.0%) and asthma reviews reach 73.0% (England 65.7%), though recorded COPD prevalence fell 3.1%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    A 71.2% working-age population and 51.5% non-White catchment may shape primary care demand

    Across 64,811 registered patients, 71.2% are aged 18-64, above Manchester (68.9%), the ICB (63.3%) and England (62.7%), while 10.8% (6,986 patients) are aged 65+, above Manchester (9.6%) but below the ICB (14.9%) and England (17.9%). Non-White ethnic groups comprise 51.5% of associated Census residents, including 23.4% Asian and 14.3% Black groups, above Manchester (20.9% and 11.9%), the ICB (13.6% and 4.7%) and England (9.6% and 4.2%). Ethnicity reflects Census area residents rather than GP registers. List growth is projected at 4.5% to 2030 under an unverified methodology.

    Age profile

    0–1718.0%
    18–6471.2%
    65+10.8%

    65+: ICB 14.9%, England 17.9%

    Ethnicity

    White48.5%
    Asian23.4%
    Black14.3%
    Other7.5%
    Mixed6.3%

    Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Manchester LA)2,3572,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)79.3%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)51.9%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Manchester LA)1,2811,0219552024/25
    Falls deaths, all ages, per 100,000 (Manchester LA)26.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 share matches England at 21.2% but practice shares span 61.3 pp

    The PCN Core20 cohort is 21.2%, below Manchester (LAD) at 59.8% and NHS Greater Manchester ICB at 40.7%, but in line with England (21.0%). Practice shares span 61.3 pp, from 6.78% at Chorlton Family Practice to 68.04% at Princess Road Surgery (2,757 estimated patients) and 48.22% at The Range Medical Centre (7,234 estimated patients). Practice estimates sum to 13,799 registered patients, whereas the resident estimate is 10,601. Targeting must distinguish concentration from volume and reconcile resident and registered bases before deploying shared outreach.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Princess Road68.0% · 2,757 patients
    Range48.2% · 7,234 patients
    Alexandra13.6% · 850 patients
    Ashville8.8% · 1,186 patients
    Wilbraham6.8% · 307 patients
    Chorlton6.8% · 1,465 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    916

    SMI register

    1.44% recorded prevalence

    524

    Learning disability register

    0.82% recorded prevalence

    17

    Care homes, 349 beds

    In the PCN catchment

    8.7%

    Provide unpaid care

    Manchester (LAD), Census 2021

    Recorded severe mental illness prevalence is 1.4% (916 patients), exceeding Manchester (1.3%), the ICB (1.1%) and England (1.0%). Learning disability register prevalence is 0.8% (524 patients), above Manchester (0.7%), the ICB (0.6%) and England (0.6%). The catchment contains 17 care homes (349 beds), though resident registrations are unconfirmed. With mental health and learning disability registers above England levels, systematic physical-health monitoring represents the priority workload to protect.

    Severe mental illness: physical health checks

    SMI recorded prevalence is 1.4% (England 1.0%). Annual physical checks trail benchmarks: 76.9% received a blood pressure check (England 83.4%) and 78.5% had a BMI recorded (England 82.1%). Local clinical audit would test recall pathways.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    6,841

    Hypertension register

    +1.34%

    Register growth, 3 yrs

    Manchester (LAD) +4.49% · England +5.60%

    +3.62pp

    BP control, under 80

    ≤140/90 · −0.92pp aged 80+

    +763

    More patients by 2030

    Forecast 7,604 (11.02%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 10.7% (6,841 patients), below England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%) but similar to Manchester (LAD) (10.5%). Recent blood pressure checks reach 85.8% (England 90.0%). Blood pressure control to target is 61.6%, trailing Manchester (LAD) (67.7%), England (70.3%) and the ICB (71.4%), with under-80 control at 59.8% (England 67.8%) and aged 80+ at 71.7% (England 81.2%). This could reflect follow-up or titration gaps, which clinical audit would test. Trailing national and borough control benchmarks indicates scope to prioritise systematic blood pressure recall and treatment titration.

    Lipids and statins

    Lipid-lowering therapy reaches 63.4% of QRISK ≥ 20% patients (Manchester (LAD) 70.5%, England 63.6%) and 68.9% of CKD patients (Manchester (LAD) 77.4%, England 70.3%). Adult lipid-regulating prescribing is 1,630 items per 1,000 (England 4,100). Lower high-risk coverage than the borough indicates an opportunity to expand primary prevention through targeted lipid reviews.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202686,559£1.90£1.94£1.86£164,462
    Cardiovascular (all), 2025114,045£2.69£3.15£3.33£306,781

    In 2026, lipid-regulating drug prescribing totaled 86,559 items at £1.90 per item (Manchester (LAD) £2.21, ICB £1.94, England £1.86), spending £3,462 more than at England's unit cost across 86,559 items; unit costs do not indicate treatment quality. Reviewing lipid-regulating drug prescribing may identify opportunities to align spend closer to national unit costs.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +4.38%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −3.14%

    Asthma prevalence, PCN 3-yr % change

    Annual reviews exceed England for COPD (79.5% vs 76.4%) and asthma (73.0% vs 65.7% across 4,248 patients), leaving about 1,100 asthma patients without a recorded review. Meanwhile, COPD recorded prevalence is 1.3% (831 patients) versus 1.9% in England, having fallen 3.1% from 2023 to 2025 (England +2.6%). Contracting registers alongside high review rates could reflect coding changes or list turnover, which case-finding audits would test.

    Cancer register and children's immunisation

    Cancer prevalence is 2.6% (1,689 patients), below England at 3.8%. Childhood immunisation coverage trails the 95.0% target. In the age-5 cohort, MMR dose 2 reaches 81.0%, trailing dose 1 (91.2%) by 10.2 pp, while the 4-in-1 booster reaches 74.1% (England 80.9%). Slower second-dose completion may reflect recall timing rather than refusal, which a cohort audit would test.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months84.9%

    England 91.0%

    6-in-1 complete primary course at 24 months92.9%

    England 92.2%

    MMR dose 1 at 24 months91.4%

    England 88.3%

    MMR dose 2 at age 581.0%

    England 82.8%

    4-in-1 pre-school booster at age 574.1%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2, above England (55.3%) but below the 75.0% national ambition by 2028 by 19.4 pp. Reaching 75% requires about 2,270 extra early-stage cases annually across the ICB; staging coverage was 70.8% (11,679 of 16,492). Locally, cervical screening is 62.0% (England 66.8%), falling 3.9% over 2023 to 2025 (England -1.0%), with lower uptake at Princess Road Surgery (42.8%) and The Range Medical Centre (49.2%). ICB figures cannot be attributed to PCN practices. Screening shortfalls at lower-uptake practices could delay early cancer detection across wider referral pathways.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    Cancer waits and diagnostics reflect acute trust performance rather than PCN delivery. For Jul 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the 62-day referral to treatment standard (standard 85.0%), compared with 74.7% at Stockport NHS Foundation Trust, 78.6% at Northern Care Alliance NHS Foundation Trust, 75.7% across NHS Greater Manchester Integrated Care Board, and 71.2% in England. On the 28-day faster diagnosis standard, Manchester University NHS Foundation Trust reached 80.1% (standard 75.0%). For diagnostics waiting 6+ weeks in Jul 2026, CT reached 14.7% (England 9.9%) and MRI reached 11.7% (England 21.4%).

    Pathways within standard (%)ManchesterNorthern Care AllianceStockportGreater Manchester ICBEngland
    28-day faster diagnosis (75%)80.0675.2083.2179.5379.32
    31-day treatment (96%)92.5494.5497.3996.4992.50
    62-day referral to treatment (85%)72.8578.6574.6775.7371.16
    Diagnostic waits over 6 weeks (%)ManchesterNorthern Care AllianceStockportEngland
    MRI11.685.091.4121.40
    CT14.664.102.939.92
    Echocardiography4.9131.4817.4628.48
    Colonoscopy4.5140.045.5330.83
    Gastroscopy29.3536.485.3129.02
    All 15 DM01 tests8.9815.7114.0823.14
    Community services activityManchester residentsGreater Manchester ICB
    Care contacts96,995573,310
    Referrals20,27094,470
    Patients with a contact31,040183,535

    Community services (residents of Manchester), Jun 2026 (provisional). In the Community Services Dataset for Jun 2026 (provisional), Manchester residents recorded 96,995 total contacts, of which 42,015 (43.3%) were with adults aged 65 and over. These borough-level community service figures describe broader local authority activity and cannot be attributed directly to PCN practices.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Easy phone contact spans 38.0 pp across practices, which could reflect differing triage models

    Across 2025/26, clinical QOF achievement reached 99.0% to 100.0% across captured practices (Princess Road Surgery 99.0%, Ashville Surgery 100.0%, Wilbraham Surgery 100.0%), against 97.1% in England. However, vaccination achievement spanned 84.4 pp, from 15.6% at Princess Road Surgery and Ashville Surgery to 100.0% at Wilbraham Surgery (England 55.2%). High clinical achievement does not ensure uniform immunisation delivery across lists.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Wilbraham Surgery886.869.3%58.6%92.6%
    Alexandra9213.681.1%72.4%92.3%
    Ashville Surgery1088.870.3%57.7%84.8%
    Range6848.260.7%87.1%76.3%
    Chorlton1116.843.1%65.9%73.3%
    Princess Road10268.059.0%66.8%70.5%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNManchester (LAD)AssetPCNManchester (LAD)
    Care homes (catchment)17 (349 beds)n/aSchools (catchment)91n/a
    Children's centres734Places of worship83289
    Libraries416Homelessness support (VCS)n/a1
    Primary schools (LA maintained)1568Primary academies850
    Special schools13

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Hypertension control and case-finding audit

    Across 6,841 hypertension patients (10.7% prevalence vs 15.2% England), blood pressure control is 61.6% vs 70.3% England; the unadjusted register gap is -28 to +3,030 patients. For discussion: run structured recall and medicines titration reviews for patients above target, alongside opportunistic blood pressure checks in high-Core20 practices. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 2

    COPD case-finding and spirometry review

    COPD prevalence is 1.3% (831 patients) vs 1.9% in Manchester (LAD) and England, falling 3.1% over 2023 to 2025 (England +2.6%); unadjusted gap is +377 to +397 patients. For discussion: audit records of smokers with repeated respiratory prescribing but no COPD code, and raise diagnostic spirometry capacity with system partners. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Asthma annual review recall

    Asthma review coverage is 73.0% across 4,248 patients (7.1% prevalence), above England's 65.7%, leaving a scale indicator of 1,148 (about 1,100) unreviewed patients. For discussion: sustain review performance using a standardised recall template and flexible or after-school review slots alongside inhaler checks. Low cost, quick to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Culturally tailored access review (p2)Asian / Asian BritishNeighbourhood health framework · Core20PLUS5 approachPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check recall (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension recall and titration audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall audit (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Practice telephony and triage audit (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Hypertension control and case-finding audit (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to targetCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 2 · COPD case-finding and spirometry review (p12)COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 monthsCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Option 3 · Asthma annual review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15